Phase I trial with peptichemio.
Thirty-two patients with tumor progression, even after conventional cytostatic drug treatment, were treated with peptichemio, with increasing doses for groups of 4 patients. The maximum tolerated dose (with minimum hematological toxicity and without any other evident toxicity) with repeated administrations, was 1.2 mg/kg twice weekly. The recommended doses for phase II trials are, as shown by the detailed analysis of the results, 0.9 mg/kg, twice weekly and administered alone, and 1.3 mg/kg, once weekly combined with other cytostatic drugs, in 500 ml of infusion fluid, with 25 mg of heparin and 25 mg of hydrocortisone to minimize the freqent risk of local phlebosclerosis.
D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D010440:Peptichemio / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D012598:Sclerosis; D014652:Vascular Diseases / Q000139:chemically induced
D009588:Nitrogen Mustard Compounds; D010440:Peptichemio